Cor Vasa 2006, 48(2):72-74 | DOI: 10.33678/cor.2006.025

Další informace o studii FIELD (Fenofibrate Intervention and Event Lowering in Diabetes]

Jiří Widimský

Published: February 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J. Další informace o studii FIELD (Fenofibrate Intervention and Event Lowering in Diabetes]. Cor Vasa. 2006;48(2):72-74. doi: 10.33678/cor.2006.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61. Go to original source... Go to PubMed...
    2. Colhoun H. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? Lancet 2005; 366:1829-31. Go to original source... Go to PubMed...
    3. Colhoun HM, Betteridge DJ, Durrington PN, for the CARDS Group. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96. Go to original source... Go to PubMed...
    4. Collins R, Armitage J, Parish S. for the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16. Go to original source... Go to PubMed...

    Return to the content